查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840753

僵直性脊椎炎市場按給藥途徑、患者年齡層、最終用戶和給藥途徑分類 - 全球預測 2025-2032

Ankylosing Spondylitis Market by Administration Route, Patient Age Group, End User, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，僵直性脊椎炎市場規模將達到 108.1 億美元，複合年成長率為 8.56%。

關鍵市場統計數據
基準年 2024 56億美元
預計年份：2025年 60.9億美元
預測年份 2032 108.1億美元
複合年成長率 (%) 8.56%

針對僵直性脊椎炎的綜合臨床和系統框架，可以讓相關人員以綜合的方式考慮治療和護理服務。

僵直性脊椎炎仍是一種複雜的發炎性疾病，對風濕病學、骨科、復健和衛生經濟學都有影響。報告的開篇概述為僵直性脊椎炎的臨床表現、不斷發展的治療方法以及不斷變化的支付方和醫療服務提供方動態提供了框架，這些因素正在影響著相關人員對診斷、治療和長期管理的方式。引言部分將近期機制方面的發現與可操作的治療路徑相結合，為臨床醫生、支付方、製造商和患者權益倡導者制定策略決策奠定了基礎。

本書重點闡述了診斷挑戰、臨床表現的多樣性以及對生活品質和功能結局的後續影響。此外，本書也著重介紹了新型生物製藥、小分子藥物和支持性治療之間的相互作用，並強調了治療方法選擇越來越受到患者合併症和給藥途徑等因素的影響。引言部分也重點介紹了數位健康工具和病患報告結局在推動更個人化的醫療服務和支援基於價值的合約討論中所發揮的作用。本部分從臨床背景轉向商業性影響，為後續章節對政策、區域動態和細分市場層面的深入分析奠定了基礎。

治療創新、診斷和醫療服務模式的革新如何協同作用，重塑僵直性脊椎炎生態系統中的臨床實踐、循證需求和支付方預期？

在治療創新、診斷技術的進步和新型護理模式的推動下，僵直性脊椎炎的治療和護理模式正在發生顯著變革時期。新型標靶治療和口服小分子藥物正在拓展傳統生物製藥以外的治療途徑，而影像學和生物標記的進步則使得早期診斷更加精準成為可能。這些轉變正在改變臨床診療流程，並提高了人們對長期疾病控制、功能保留和降低併發症負擔的期望。

同時，支付方模式和合約方式也在不斷演變，以獎勵療效和依從性，這促使製造商重新思考證據生成和患者支持基礎設施。數位療法和遠端監測工具的普及為支持長期參與和依從性創造了機遇，但也對互通性和數據管治提出了新的要求。因此，成功的相關人員將是那些能夠將臨床價值提案與實際交付模式相結合、投資於真實世界證據生成並設計差異化病患准入計畫的機構。本章將探討這些變革性趨勢如何交織，並概述其對臨床開發、商業化和醫療系統整合的策略意義。

關稅政策變化對僵直性脊椎炎治療藥物供應鏈、籌資策略和商業性韌性的實際影響

2025年關稅政策調整的累積影響，為生物製藥價值鏈的供應鏈設計、籌資策略和定價結構帶來了新的考量。更高的進口關稅和日益複雜的關稅體系，凸顯了在地化生產決策和分銷網路彈性的重要性。製造商和經銷商現在必須權衡集中化生產的效率優勢與區域或國內產能帶來的成本節約之間的利弊。

這些政策發展不僅會影響到岸成本的即時調整，還會影響與醫療體系的合約談判。由於採購團隊會將關稅相關的成本差異納入採購決策，因此與醫療系統和支付方的合約談判也會受到影響。同時，各公司正在加快制定應急計劃，包括策略性儲備、多通路採購以及對大宗商品進行選擇性區域化，以維持利潤率穩定和供應連續性。合規性和海關彈性已成為競爭優勢，凸顯了商業、供應鏈和法律團隊之間跨職能協調的必要性。展望未來，相關人員，將更有利於進入市場並保持營運韌性。

高解析度細分分析將給藥途徑、年齡層和最終用戶偏好與實際治療路徑和商業優先事項聯繫起來。

在僵直性脊椎炎領域，細分市場層面的細微差別是影響臨床應用、患者體驗和商業化策略的關鍵因素。根據給藥途徑，本研究對注射劑、靜脈注射劑和口服製劑的市場進行了分析。注射劑又進一步細分為靜脈注射劑和皮下注射劑。口服製劑則進一步細分為膠囊劑和錠劑。我們揭示了給藥途徑如何影響患者依從性、臨床監測需求和臨床經濟效益，其中皮下注射劑的優勢在於門診病人的便利性，而靜脈注射劑則更側重於輸注給藥。

患者的異質性也會影響需求和治療路徑。根據患者年齡層，市場研究分別針對成人、老年人和兒童。年齡差異會影響合併症情況、安全考量和決策優先事項，並體現在標籤策略和藥物流行病學計劃中。最終用戶動態決定了醫療服務的提供地點和支援服務的建構方式：根據最終用戶，市場研究分別針對居家照護中心、醫院和專科診所。每種機構的報銷、人員配備和監測能力各不相同，這些都會影響產品定位和服務設計。

最後，我們進一步依給藥途徑細分。依給藥途徑，我們考察注射劑、口服劑和局部劑。注射劑進一步細分為靜脈注射和皮下注射。口服劑涵蓋溶液劑和片劑。局部劑進一步細分為乳膏劑和凝膠劑。這種細緻的框架有助於明確研發優先順序、定價策略和病患援助計畫的設計，使製劑選擇與實際使用模式和臨床實際情況相符。

制定區域策略，以適應美洲、歐洲、中東和非洲以及亞太地區不同的報銷制度、供應鏈限制和採用模式。

區域動態仍是策略規劃的核心，因為臨床實務、報銷體系和供應鏈的實際情況在各大全球區域之間存在顯著差異。美洲地區繼續強調基於價值的合約和整合式醫療路徑，並擁有先進的支付方流程，獎勵持久療效和真實世界證據的收集。相較之下，歐洲、中東和非洲的報銷和監管環境各不相同，更有利於制定區域性進入策略和協調定價。在亞太地區，一些市場正在經歷新治療方法的快速普及，而另一些市場則面臨成本限制，這導致市場准入和規模化發展面臨不同的考量。

這些地域差異會影響市場進入順序、證據累積的優先事項以及合作夥伴的選擇。早期聚焦於特定的高價值細分市場通常能夠提供可供更廣泛的地理推廣的驗證點。此外，在地化生產、監管協調以及經銷夥伴在降低這些地區的關稅和物流風險方面發揮著至關重要的作用。因此，針對不同地區量身定做的策略，既要平衡統一的臨床價值訊息，又要兼顧區域營運策略，對於在美洲、歐洲、中東和非洲以及亞太地區持續獲得市場認可和推廣至關重要。

透過證據產生、在地化生產和整合患者支持來定義競爭優勢的競爭策略和夥伴關係模式

在僵直性脊椎炎領域，競爭格局日益凸顯，整合了治療效果、病患支持服務和數據主導的證據產生等綜合解決方案。以研發為導向的生物製藥公司持續投資，透過靶向管線產品和拓展適應症來提升臨床差異化；而專科生物製藥公司則專注於機制創新和市場定位。同時，口服小分子藥物和學名藥生產商正利用製劑改進和差異化給藥系統來搶佔治療鏈的各個環節。

整個生態系統內的夥伴關係正在加速發展，製藥公司與專業服務供應商攜手合作，提供涵蓋依從性、監測和療效評估的綜合解決方案。診斷和影像公司正深化與臨床相關人員的合作，以支援早期檢測和長期疾病管理，而受託製造製造商則在調整生產模式，以滿足對本地化生產能力的需求。總而言之，這些公司層面的趨勢意味著，策略聯盟、靈活的生產模式以及強大的真實世界證據能力將決定誰能夠持續創造臨床和商業性價值。

一套切實可行的策略方案，旨在透過證據產生、供應鏈靈活性和以患者為中心的交付方式，獲取治療和商業性價值。

產業領導者應優先採取一系列切實可行的措施，使臨床差異化與商業性可行性和營運韌性一致。首先，投資整合證據計劃，結合隨機對照試驗、真實世界臨床試驗和病患報告結局，向支付者和臨床醫生證明其長期價值。其次，重新思考供應鏈佈局，在集中效率和區域彈性之間取得平衡，以因應關稅變化和採購差異。第三，設計以病人為中心的交付模式，考慮給藥途徑偏好和臨床試驗中心的經濟效益，從而兼顧依從性和成本效益。

此外，我們將加強與診斷、數位醫療和專科護理網路之間的策略夥伴關係，以推進早期診斷和持續疾病監測。我們將實施靈活的合約選項和風險分擔機制，使其與當地的醫保報銷政策相符，從而加快市場准入並降低支付方的阻力。最後，我們將優先發展數據分析和監管事務的能力，將真實世界的洞察轉化為擴大適應症範圍和差異化報銷的討論。這些措施將有助於把臨床創新轉化為以患者為中心、永續的商業性成果。

採用透明的多方法研究途徑，結合一手訪談、二手文獻綜合和三角驗證分析，確保獲得可靠的策略洞察。

本報告的調查方法結合了質性研究、嚴謹的二手資料和結構化資料綜合，以確保結論的可重複性和可操作性。定性研究包括對臨床醫生、醫保專家、供應鏈高管和患者權益倡導代表進行深度訪談，以深入了解治療模式、就醫障礙和實際治療偏好。這些訪談旨在揭示營運中的細微差別，並檢驗假設驅動的分析框架。

二次研究透過整契約行評審文獻、監管指南、臨床實踐建議和公開的衛生系統報告，對主要研究結果進行了補充。研究採用資料三角測量技術，協調不同資訊來源的觀點，並增強解釋的可靠性。透過反覆的同儕審查、方法透明化以及對資訊來源和解釋的品質檢查，確保了分析方法的嚴謹性。在適用情況下，研究也運用了敏感度分析和情境規劃，以檢驗策略影響的穩健性，並為臨床、商業和政策領域的相關人員提供更靈活的建議。

整合臨床、商業性和營運方面的必要因素，領導者必須協調一致，才能將治療進展轉化為持續的患者和系統層面的價值。

總而言之，僵直性脊椎炎領域呈現出臨床創新、不斷演進的護理模式以及營運壓力並存的特點，這既為相關人員帶來了機遇，也帶來了挑戰。治療方法多樣化、診斷技術的進步以及數位醫療的整合正在重塑患者的診斷和管理方式，而支付方和採購機制的變化則要求更精細的價值溝通和更具適應性的供應策略。給藥途徑、患者族群特徵和治療環境之間的相互作用，進一步影響治療在何處以及如何真正發揮臨床療效。

策略成功取決於將實證實踐與務實的商業化策略相結合，投資於靈活的生產和分銷，並建立超越傳統產品中心模式的夥伴關係。專注於病患療效、在地化特色和靈活的營運設計，有助於機構克服政策變革和推廣應用方面的障礙，同時提供更優質的醫療服務。結論強調，需要採取審慎且全面的方法，將科學進步轉化為持久的患者獲益和永續的商業性績效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 白細胞介素-17抑制劑的出現，提高了僵直性脊椎炎。
  • 生物相似藥腫瘤壞死因子抑制劑的快速上市降低了治療成本，並提高了僵直性脊椎炎患者獲得治療的機會。
  • 整合遠端醫療和遠端患者監護平台，以提高僵直性脊椎炎臨床管理中的依從性和早期病情復發檢測。
  • 透過基於HLA-B27基因分型和生物標記分析的個人化治療流程的進步，實現標靶治療
  • 增加對JAK抑制劑治療僵直性脊椎炎的投資，並評估其與生物製藥相比的長期安全性
  • 利用病患登記的真實世界證據，了解新治療方法的長期療效和安全性。
  • 擴大支付方和生產商之間基於價值的合約模式，以最佳化結果並控制成本。
  • 一項新研究探討了腸道菌叢調節作為控制發炎的新治療方法。
  • 開發數位化物理治療和運動指導應用程式，以提高患者參與度和改善護理中的功能性結果。
  • 新一代小分子抑制劑獲得監管部門核准，拓寬了難治性僵直性脊椎炎的治療前景

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章僵直性脊椎炎市場（依給藥途徑分類）

  • 注射
    • 靜脈輸液
    • 皮下注射
  • 靜脈
  • 口服
    • 膠囊
    • 藥片

第9章 依患者年齡層分類的僵直性脊椎炎市場

  • 成人版
  • 老年人
  • 孩子們

第10章僵直性脊椎炎市場（依最終用戶分類）

  • 居家護理中心
  • 醫院
  • 專科診所

第11章僵直性脊椎炎市場（依給藥途徑分類）

  • 注射
    • 靜脈輸液
    • 皮下注射
  • 口服
    • 解決方案
    • 藥片
  • 話題
    • 奶油
    • 凝膠

第12章僵直性脊椎炎市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章僵直性脊椎炎市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國僵直性脊椎炎市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Novartis AG
    • Pfizer Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Galapagos NV
    • Gilead Sciences, Inc.
    • Sandoz International GmbH
Product Code: MRR-A339DAEFAA9A

The Ankylosing Spondylitis Market is projected to grow by USD 10.81 billion at a CAGR of 8.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.60 billion
Estimated Year [2025] USD 6.09 billion
Forecast Year [2032] USD 10.81 billion
CAGR (%) 8.56%

Comprehensive clinical and systemic framing of ankylosing spondylitis to orient stakeholders toward integrated therapeutic and care-delivery considerations

Ankylosing spondylitis remains a complex inflammatory condition with implications across rheumatology, orthopedics, rehabilitation, and health economics. This report's opening synthesis frames the clinical profile, evolving therapeutic approaches, and the shifting payer and care-delivery dynamics that shape how stakeholders approach diagnosis, treatment, and long-term management. By situating recent mechanistic discoveries alongside pragmatic treatment pathways, the introduction sets a foundation for strategic decisions by clinicians, payers, manufacturers, and patient advocates.

The narrative emphasizes diagnostic challenges, the heterogeneity of clinical presentation, and the downstream effects on quality of life and functional outcomes. It also foregrounds the interplay between novel biologics, small molecules, and supportive care modalities, highlighting how therapeutic selection increasingly depends on patient comorbidities and route-of-administration considerations. Furthermore, the introduction underscores the role of digital health tools and patient-reported outcomes in driving more personalized care and in supporting value-based contracting discussions. Transitioning from clinical context to commercial implications, this section prepares readers for deeper analysis of policy, regional dynamics, and segment-level insights that follow in subsequent chapters.

How therapeutic innovation, diagnostics, and care-delivery redesign are jointly reshaping clinical practice, evidence needs, and payer expectations across the ankylosing spondylitis ecosystem

The treatment and care landscape for ankylosing spondylitis is undergoing a period of substantive transformation driven by therapeutic innovation, enhanced diagnostics, and new care models. Emerging targeted agents and oral small molecules are expanding the armamentarium beyond traditional biologic classes, while advances in imaging and biomarkers are enabling earlier and more precise diagnosis. These shifts are altering clinical algorithms and increasing expectations for sustained disease control, functional preservation, and reduced comorbidity burden.

Concurrently, payer models and contracting approaches are evolving to reward outcomes and adherence, prompting manufacturers to rethink evidence generation and patient-support infrastructures. Digital therapeutics and remote monitoring tools are gaining traction, creating opportunities for long-term engagement and adherence support but also placing new demands on interoperability and data governance. As a result, successful stakeholders are those aligning clinical value propositions with pragmatic delivery models, investing in real-world evidence generation, and designing differentiated patient access programs. This chapter explores how these transformative currents intersect, and it outlines the strategic implications for clinical development, commercialization, and health-system integration.

Practical implications of tariff policy changes on supply chains, procurement strategies, and commercial resilience for ankylosing spondylitis therapies

The cumulative effects of tariff policy shifts in 2025 introduced new considerations for supply chain design, procurement strategies, and pricing architecture across the biopharmaceutical value chain. Increased import duties and tariff complexity have elevated the importance of local manufacturing footprint decisions and the flexibility of distribution networks. Manufacturers and distributors must now weigh the trade-offs between centralized production efficiencies and the cost mitigation benefits of regional or in-country production capabilities.

These policy developments have implications beyond immediate landed cost adjustments. They affect contractual negotiations with health systems and payers, as procurement teams integrate tariff-related cost variability into sourcing decisions. In parallel, companies are accelerating contingency planning to preserve margin stability and continuity of supply, including strategic stockpiling, multi-sourcing, and selective regionalization of high-volume product lines. Regulatory compliance and customs agility have become competitive differentiators, underscoring the need for cross-functional coordination between commercial, supply chain, and legal teams. Moving forward, stakeholders that proactively model tariff exposure and embed flexible manufacturing and distribution options into their commercial playbooks will be better positioned to sustain market access and operational resilience.

High-resolution segmentation analysis linking administration route, age cohorts, and end-user settings to real-world treatment pathways and commercial priorities

Segment-level nuance is a critical determinant of clinical adoption, patient experience, and commercialization strategy in ankylosing spondylitis. Based on Administration Route, market is studied across Injectable, Intravenous, and Oral. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Capsules and Tablets. This perspective clarifies how route of administration influences adherence patterns, clinical monitoring needs, and site-of-care economics, with subcutaneous formulations offering outpatient convenience and intravenous options concentrated in infusion settings.

Patient heterogeneity also shapes demand and care pathways; based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric. Age-related differences affect comorbidity profiles, safety considerations, and shared decision-making priorities, thereby informing label strategies and pharmacoepidemiology plans. End-user dynamics determine where care is delivered and how support services are structured: based on End User, market is studied across Homecare Centers, Hospitals, and Specialty Clinics. Each setting has distinct reimbursement, staffing, and monitoring capabilities that influence product positioning and services design.

Finally, route-specific segmentation is further refined: based on Route Of Administration, market is studied across Injectable, Oral, and Topical. The Injectable is further studied across Intravenous Infusion and Subcutaneous Injection. The Oral is further studied across Solutions and Tablets. The Topical is further studied across Creams and Gels. This granular framework helps clarify R&D prioritization, pricing strategy, and patient support program design by aligning formulation choices with real-world use patterns and site-of-care realities.

Regionally calibrated strategies to reconcile divergent reimbursement systems, supply-chain constraints, and adoption patterns across the Americas, EMEA, and Asia-Pacific

Regional dynamics remain central to strategic planning, as clinical practice, reimbursement frameworks, and supply-chain realities vary significantly across major world regions. The Americas continue to demonstrate a strong emphasis on value-based contracting and integrated care pathways, with advanced payer processes that incentivize durable outcomes and real-world evidence collection. In contrast, Europe, Middle East & Africa show heterogeneous reimbursement landscapes and regulatory approaches that favor region-specific access strategies and collaborative pricing arrangements. Asia-Pacific presents rapid uptake of new modalities in some markets alongside cost-constrained environments in others, creating a diverse set of market-entry and scale-up considerations.

These geographic differences affect go-to-market sequencing, evidence-generation priorities, and partner selection. In many cases, early commercial focus on specific high-value submarkets enables proof points that can be adapted for broader regional rollout. Moreover, local manufacturing, regulatory harmonization efforts, and distribution partnerships play pivotal roles in mitigating tariff and logistic exposure across these regions. Accordingly, a regionally calibrated approach that balances uniformity of clinical value messaging with localized operational tactics will be essential for sustained access and uptake across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Corporate strategies and partnership models that are defining competitive advantage through evidence generation, localized manufacturing, and integrated patient support

Competitive dynamics in ankylosing spondylitis are increasingly defined by integrated offerings that combine therapeutic efficacy with patient support services and data-driven evidence generation. Established biopharmaceutical firms continue to invest in clinical differentiation through targeted pipeline assets and extended indication development, while specialty biotech companies focus on mechanistic innovation and niche positioning. Concurrently, manufacturers of oral small molecules and generics are leveraging formulation improvements and differentiated delivery systems to capture segments of the treatment continuum.

Partnerships across the ecosystem are accelerating, with collaborations between pharma companies and specialty service providers enabling bundled solutions that address adherence, monitoring, and outcomes measurement. Diagnostics and imaging firms are deepening engagement with clinical stakeholders to support earlier detection and longitudinal disease management, and contract manufacturing organizations are adapting to demand for more localized production capacity. Collectively, these company-level trends point toward a landscape where strategic alliances, flexible manufacturing models, and robust real-world evidence capabilities determine who can deliver sustained clinical and commercial value.

Actionable strategic playbook for aligning evidence generation, supply-chain flexibility, and patient-centric delivery to capture therapeutic and commercial value

Industry leaders should prioritize a set of actionable measures that align clinical differentiation with commercial viability and operational resilience. First, invest in integrated evidence plans that combine randomized trials, pragmatic real-world studies, and patient-reported outcomes to substantiate long-term value for payers and clinicians. Second, reassess supply-chain footprints to balance centralized efficiencies with regional agility, enabling responsiveness to tariff shifts and procurement variability. Third, design patient-centric delivery models that account for administration-route preferences and site-of-care economics, supporting both adherence and cost-effectiveness.

In addition, cultivate strategic partnerships across diagnostics, digital health, and specialty care networks to accelerate early diagnosis and continuous disease monitoring. Embed flexible contracting options and risk-sharing arrangements tailored to regional reimbursement realities to facilitate market access and reduce payer resistance. Finally, prioritize capability-building in data analytics and regulatory affairs to translate real-world insights into label expansions and differentiated reimbursement conversations. Collectively, these actions will enable organizations to convert clinical innovation into sustainable, patient-centered commercial outcomes.

Transparent, multi-method research approach combining primary interviews, secondary literature synthesis, and triangulated analysis to ensure credible strategic insights

The research methodology underpinning this report combines primary qualitative inquiry with rigorous secondary intelligence and structured data synthesis to ensure reproducibility and actionable clarity. Primary research involved in-depth interviews with clinicians, reimbursement specialists, supply-chain executives, and patient advocacy representatives to capture practical insights on care patterns, access barriers, and real-world treatment preferences. These conversations were designed to illuminate operational nuances and to validate hypothesis-driven analytic frameworks.

Secondary research complemented primary findings by consolidating peer-reviewed literature, regulatory guidance, clinical practice recommendations, and publicly available health-system reports. Data triangulation techniques were applied to reconcile differing source perspectives and to strengthen the reliability of interpretation. Analytic rigor was maintained through iterative peer review, methodological transparency, and quality checks on sourcing and interpretation. Where applicable, sensitivity analysis and scenario planning were used to test the robustness of strategic implications, supporting more resilient recommendations for stakeholders across clinical, commercial, and policy domains.

Synthesis of clinical, commercial, and operational imperatives that leaders must align to translate therapeutic progress into durable patient and system-level value

In sum, the ankylosing spondylitis landscape is characterized by clinical innovation, evolving care models, and operational pressures that together create both opportunity and complexity for stakeholders. Therapeutic diversification, enhanced diagnostics, and digital health integration are reshaping how patients are diagnosed and managed, while payer and procurement dynamics necessitate more sophisticated value communication and adaptive supply strategies. The interplay between administration routes, patient demographics, and care settings further refines where and how treatments will achieve meaningful clinical impact.

Strategic success will depend on aligning evidence-generation efforts with pragmatic commercialization tactics, investing in flexible manufacturing and distribution, and building partnerships that extend beyond traditional product-centric models. By focusing on patient outcomes, regional particularities, and resilient operational design, organizations can navigate policy shifts and adoption hurdles while delivering improved care. The conclusion emphasizes that deliberate, integrated approaches will be required to translate scientific progress into lasting patient benefit and sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of interleukin-17 inhibitors showing enhanced symptom control and reduced radiographic progression in ankylosing spondylitis patients
  • 5.2. Rapid adoption of biosimilar tumor necrosis factor blockers driving cost savings and increased patient access to ankylosing spondylitis therapies
  • 5.3. Integration of telemedicine and remote patient monitoring platforms to improve adherence and early flare detection in AS clinical management
  • 5.4. Advances in personalized treatment algorithms guided by HLA-B27 genotyping and biomarker profiling for targeted ankylosing spondylitis care
  • 5.5. Growing investment in JAK inhibitors for ankylosing spondylitis and evaluation of their long term safety compared to biologics
  • 5.6. Utilization of real world evidence from patient registries to inform long term efficacy and safety profiles of emerging ankylosing spondylitis therapies
  • 5.7. Expansion of value based contracting models between payers and manufacturers to optimize outcomes and control costs in ankylosing spondylitis treatment
  • 5.8. Emerging research into gut microbiome modulation as a novel therapeutic approach for inflammation control in ankylosing spondylitis
  • 5.9. Development of digital physiotherapy and exercise coaching apps to enhance patient engagement and functional outcomes in ankylosing spondylitis care
  • 5.10. Regulatory approvals of next generation small molecule inhibitors broadening the treatment landscape for refractory ankylosing spondylitis cases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ankylosing Spondylitis Market, by Administration Route

  • 8.1. Injectable
    • 8.1.1. Intravenous Infusion
    • 8.1.2. Subcutaneous Injection
  • 8.2. Intravenous
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Tablets

9. Ankylosing Spondylitis Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Ankylosing Spondylitis Market, by End User

  • 10.1. Homecare Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Ankylosing Spondylitis Market, by Route Of Administration

  • 11.1. Injectable
    • 11.1.1. Intravenous Infusion
    • 11.1.2. Subcutaneous Injection
  • 11.2. Oral
    • 11.2.1. Solutions
    • 11.2.2. Tablets
  • 11.3. Topical
    • 11.3.1. Creams
    • 11.3.2. Gels

12. Ankylosing Spondylitis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Ankylosing Spondylitis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Ankylosing Spondylitis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Novartis AG
    • 15.3.3. Pfizer Inc.
    • 15.3.4. Amgen Inc.
    • 15.3.5. Eli Lilly and Company
    • 15.3.6. Galapagos NV
    • 15.3.7. Gilead Sciences, Inc.
    • 15.3.8. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOMECARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN ANKYLOSING SPONDYLIT